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Background: Type 2 diabetes (T2D) is associated with reduction and dysfunction of circulating pro-angiogenic cells
(PACs). DPP-4 inhibitors, a class of oral agents for T2D, might possess pleiotropic vasculoprotective activities. Herein,
we tested whether DPP-4 inhibition with Saxagliptin affects the function of circulating PACs from T2D and healthy
subjects.
Methods: PACs were isolated from T2D (n = 20) and healthy (n = 20) subjects. Gene expression, clonogenesis,
proliferation, adhesion, migration and tubulisation were assessed in vitro by incubating PACs with or without
Saxagliptin and SDF-1α. Stimulation of angiogenesis by circulating cells from T2D patients treated with Saxagliptin
or other non-incretinergic drugs was assessed in vivo using animal models.
Results: Soluble DPP-4 activity was predominant over cellular activity and was successfully inhibited by Saxagliptin.
At baseline, T2D compared to healthy PACs contained less acLDL+Lectin+ cells, and showed altered expression of
genes related to adhesion and cell cycle regulation. This was reflected by impaired adhesion and clonogenesis/
proliferative response of T2D PACs. Saxagliptin + SDF-1α improved adhesion and tube sustaining capacity of PACs
from T2D patients. CD14+ PACs were more responsive to Saxagliptin than CD14− PACs. While Saxagliptin modestly
reduced angiogenesis by mature endothelial cells, circulating PACs-progeny cells from T2D patients on Saxagliptin
treatment displayed higher growth factor-inducible in vivo angiogenetic activity, compared to cells from T2D
patients on non-incretinergic regimen.
Conclusions: Saxagliptin reverses PACs dysfunction associated with T2D in vitro and improves inducible
angiogenesis by circulating cells in vivo. These data add knowledge to the potential pleiotropic cardiovascular
effects of DPP-4 inhibition.
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Type 2 diabetes (T2D) increases the risk of cardiovascular
disease 2–3 fold. This is attributed to excess endothelial
damage resulting from hyperglycemia and associated
metabolic abnormalities, as well as impaired vascular
repair [1]. Circulating cells with vascular repair and
pro-angiogenic capacity are reduced and functionally* Correspondence: gianpaolo.fadini@unipd.it
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unless otherwise stated.impaired in T2D [2-4], which is believed to contribute
to diabetic vascular and cardiac disease [5,6]. While
reduction of circulating progenitors and endothelial
progenitor cells (EPCs) in diabetes is much likely caused
by impaired mobilization from the bone marrow [7].
dysfunction of circulating pro-angiogenic cells (PACs)
results from the adverse metabolic milieu of T2D [8].
It has been reported that EPCs/PACs reduction and
dysfunction is, to some extent, reversible by drugs
commonly used for the treatment of T2D [9]. Several
different phenotypes and culture methods have been
described for so-called “EPCs” [10], We herein focus onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Poncina et al. Cardiovascular Diabetology 2014, 13:92 Page 2 of 16
http://www.cardiab.com/content/13/1/92hematopoietic-derived early EPCs, also known as circu-
lating angiogenic cells (CACs) or PACs, because they
can be easily and reproducibly isolated from peripheral
blood of healthy and diseased subjects, while late EPCs
or ECFC (endothelial colony forming cells) have stochastic
appearance in culture [2,10].
Dipeptidyl peptidase (DPP)-4 inhibitors (DPP-4i) are
currently used for the management of T2D, as they pre-
vent the degradation of endogenous incretin hormones
(glucagon-like peptide-1 [GLP-1] and glucose-dependent
insulinotropic peptide [GIP]), leading to meal-induced
insulin secretion. In addition to incretins, DPP-4 has
several other physiologic substrates, including cytokines,
chemokines, and neurohormones that can affect vascular
function and metabolism [11]. By inhibiting the enzymatic
degradation of such factors, DPP-4i have the potential to
exert pleiotropic cardiovascular effects [12]. Interestingly,
stromal cell-derived factor (SDF)-1α is a natural DPP-4
substrate and a major regulator of stem cell mobilization
[13], as well as EPCs/PACs function [14]. We have previ-
ously shown that a short-term treatment with the DPP-4i
Sitagliptin is able to increase circulating EPCs in T2D,
likely via SDF-1α [15]. In addition, data obtained in animal
models suggest potential benefit of DPP-4 inhibition on
EPC pro-angiogenic activity [16,17].
Herein, we tested the hypothesis that DPP-4i can affect
the function of PACs from T2D patients, using in vitro
and in vivo assays. As SDF-1α is the major candidate
mediator that translates DPP-4 inhibition into improved
PACs function, in vitro experiments were performed
with and without concomitant SDF-1α supplementation.
Methods
Patients
The study was approved by the Ethical Committee of the
University Hospital of Padova and was conducted in ac-
cordance with the principles of the Declaration of Helsinki
as revised in 2008 Informed consent was obtained from
patients. Type 2 diabetic patients were recruited at the
outpatient clinic of the Metabolic Division, University
Hospital of Padova. Healthy blood donor subjects were
recruited anonymously from the local blood biobank,
provided they were free from diabetes and cardiovascular
disease. For diabetic patients, the following data were
collected from the electronic outpatient clinic charts:
age, sex, BMI, waist circumference, systolic and diastolic
blood pressure. diabetes duration, HbA1c, lipid profile,
concomitant risk factors, complications and medications.
Coronary artery disease was defined as a past history of
myocardial infarction of angina confirmed by a coronary
angiography showing stenosis >70% in at least one epicar-
dial coronary vessel, or in the presence of a non-invasive
stress test indicative of inducible myocardial ischemia.
Peripheral arterial disease was defined as claudication,rest pain, or ischemic diabetic foot confirmed by an
angiographic or ultrasound examination. Cerebrovascular
disease was defined as a past history of stroke or evidence
of carotid artery stenosis >30% at a ultrasound examination.
Retinopathy was defined based on digital funduscopic
photography scored remotely by expert ophthalmologists.
Nephropathy was defined as overt macroalbuminuria
(urinary albumin/creatinin ratio [ACR] > 300 mg/g) or as
chronic renal failure (estimated glomerular filtration rate
[eGFR] < 60 ml/min/1.73 m2). As the 2.5 mg renal dose-
adjusted formulation of Saxagliptin was not yet commer-
cially available in Italy when the study was performed,
none of the patients in the in vivo study had chronic renal
failure. Data on medications were also collected. For the
in vivo angiogenesis assay, patients on Saxagliptin treat-
ment (n = 5) since >4 months and patients on other, non-
incretinergic, regimen (n = 5) were enrolled. As treatment
had been previously decided on clinical ground and was
not assigned by the investigators, this did not represent a
clinical trial and was not registered as such.
Culture of pro-angiogenic cells (PACs) and functional
assessment
PBMCs were isolated by density gradient centrifugation with
Histopaque-1077. Cells were plated on human fibronectin-
coated culture dishes and maintained in endothelial cell
basal medium-2 (EBM-2). The medium was supplemented
with EGM-2 MV SingleQuots containing FBS (5%), human
VEGF-1, human fibroblast growth factor-2 (FGF-2), human
epidermal growth factor (EGF), insulin-like growth factor-1
(IGF-1), and ascorbic acid. After 4 days in culture, non-
adherent cells were removed by washing with PBS, new
medium was applied, and the cells were maintained
through day 7 cultured with or without Saxagliptin (Saxa,
DPP-4 inhibitor) and with or without SDF-1α.
PACs obtained after 7 days of culture without stimuli
were immunophenotyped by fluorescence microscopy
(Leica DM 6000B) for the ability to uptake AcLDL and
bind FITC-Ulex europaeus agglutinin Lectin. Adherent
cells were first incubated with Dil-acLDL for 1 h, then
counterstained with FITC-Lectin and fixed in 2% para-
formaldehyde. Images were acquired with the manufac-
turer’s software, and assembled using Adobe Photoshop.
In separate experiments, PACs were cultured from unse-
lected PBMCs of healthy controls in the presence of Saxa-
gliptin and/or SDF-1α and, at the end of the 7 day culture
period, CD14+ PACs were separated from CD14− PACs
using the MS Column and MiniMACS Separator (Miltenyi
Biotec). Then, functional assays and gene expression were
analyzed separately for CD14+ and CD14− PACs.
Adhesion assay
A monolayer of human umbilical vein endothelial cells
(HUVECs) was prepared 48 hours before the assay by
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well plate. PACs were labeled with CMTMR and 1 × 105
cells were added to each well and incubated for 3 hours
at 37°C. Non attached cells were gently removed with
PBS, and adherent PACs were fixed with 4% paraformal-
dehyde and counted in 10 randomly selected field.
Matrigel tubule assay
Matrigel (Sigma-Aldrich) was thawed and placed in 96-
well plate at room temperature for 30 minutes to allow
solidification. PACs (3 × 103) were co-plated with 1.5 × 104
human umbilical vein endothelial cells (HUVECs) and
incubated at 37°C for 24 hours. The 5:1 HUVECs/PACs
ration was chosen based on a preliminary dose–response
experiments (not shown), which showed a suppressive ef-
fect of higher ratios on tube formation. Tubule formation
was defined as a structure exhibiting a length 4 times its
width. The length and the number of tubules was deter-
mined in 10 randomly selected fields.
In separate experiments performed to analyze the
physical location of PACs co-cultured with HUVECs in
the Matrigel tubule assay, PACs were red-labelled with
the fluorescent dye Cell-Tracker Orange CMTMR (Life
Technologies).
Migration assay
Cell migratory assays were performed using Transwell
chambers with filter membranes of 3 mm pore size.
Transwell chambers were inserted into the plate wells.
PACs were seeded into the upper chamber (104 cells per
well in serum-free medium) in either the absence or the
presence of SDF-1α at 37°C. At the end of the assay,
3 hours later, migrated PACs in the lower compartment
were collected and counted using the flow cytometer.
Results are reported as ratio of the number of migrated
cells and non migrated cells.
Flow cytometry and immunomagnetic cell sorting
For the characterization of PACs, cells were detached
using EDTA and scraping. Cells were labelled with mouse
anti-human PerCP-Cy5.5 CD45 (BD Pharmingen, cat#
552724), PE KDR (R&D Systems, cat# FAB357P), FITC
CD68 (Dako Cytomation, cat#F7135), APC CD34 (BD
Pharmingen, cat# 345804), PE CD14 (Beckman Coulter,
cat# A07764), FITC CD26 (BD Pharmingen, cat# 555436),
FITC CD31 (BD Pharmingen, cat# 555445). Events were
acquired using a FacsCanto instrument (BD), after mor-
phological gating in the SSC vs FSC plot. Al least 105
events were acquired for each analysis.
PACs treated with and without Saxagliptin and/or
SDF-1α for 7 days were trypsinized into conical tubes,
washed twice with PBS and fixed in 70% ice-cold ethanol.
For DNA analysis, cells were centrifuged at 200 g for
10 min at 4°C and washed twice with PBS. For cell cycleanalysis, after incubation at 37°C in the dark for 15 min,
DNA content of the nuclei was determined by staining
nuclear DNA with propidium iodide solution (50 μg/mL,
sigma, USA) containing 50 μg/mL ribonuclease A. The
DNA content was measured by a flow cytometry
(FacsCanto) and scored.
For immunomagnetic selection of CD14pos and
CD14neg cells out of the initial PBMC population for
PACs culture, we used the MS Column and MiniMACS
Separator (Miltenyi Biotec). After isolation of PBMCs,
cells were centifugated at 300 g for 10 minutes. The cell
pellets were resuspended in 80 μL of buffer (MACS buf-
fer), 20 μl of CD14 MicroBeads per 107 total cells were
added. After 30 minutes in the refrigerator, cells was
washed by adding MACS buffer and resuspended in
500 μL of buffer. The magnetic separation was per-
formed as described by the manufactures.
Determination of DPP-4 activity
DPP-4 activity was determined in conditioned medium or
cell extracts from cell cultures using the DPP-4 drug
discovery Kit (Enzo Life Sciences, Farmingdale, NY, USA)
with the Gly-Pro-para-nitroaniline (pNA) chromogenic
substrate, according to the manufacturer’s instructions.
Gene expression analysis
After 7 days of culture total RNA was extracted from
PACs using RNeasy kit (Qiagen), following the manu-
facturer’s protocol. RNA quantity was determined on a
Nanodrop Spectrometer (termo Fisher scientific Inc)
(using 1 OD260 = 40 μg RNA). A260/A280 ratios were
also calculated for each sample. RNA was reverse tran-
scribed to generate cDNA using the First-Strand cDNA
Synthesis Kit from Invitrogen following the manufacturer’s
protocol. Samples were mixed by vortexing and briefly
centrifuged and denaturated by incubation for 5 minutes
at 70°C to prevent secondary structures of RNA. Samples
were incubated on ice for 2 minutes to allow the primers
to align. Gene-specific primer pairs were designed using
Primer-BLAST (NCBI) and were each validated prior to
use by gradient PCR and gel analysis to test for optimal
annealing temperature, reaction efficiency and specificity
(Table 1). Duplicates of sample cDNA were then amplified
on the 7900HT Fast Real-Time PCR System (Applied Bio-
systems) using the Fast SYBR Green RT-PCR kit (Applied
Biosystems) in 96-wells plates (micro amp optical, Applied
Biosystems). Expression data were normalized to the mean
of housekeeping gene to control the variability in expres-
sion levels and were analyzed using the 2-ΔCT method.
Mouse colony forming assay
Hematopoietic colonies were grown from unfractioned
bone marrow cells of C57Bl/6 mice and quantified using
the Methocult system (Stem Cells inc. Vancouver,
Table 1 Primer sequences for real time PCR analysis
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of laboratory animal care’ (NIH publication no. 85–
23, revised 1985; http://grants1.nih.gov/grants/olaw/
references/phspol.htm) as well as specific national laws
were followed.
Spheroid assay
For preparation of methocoel, 6 g of methyl-cellulose
together with a magnetic stir bar were autoclaved in a
500 ml flask. Afterwards, 250 ml of 60°C basal EBM
medium was added under sterile conditions and the
suspension was stirred at 60°C for 40 min. Additional
250 ml of basal EBM medium were added and the solu-
tion was stirred at 4°C overnight. 50 ml portion of the
solution were centrifuged for 2 h at 4000 rpm at room
temperature. The highly viscose soluble fraction was
separated from insoluble residue and was stored at 4°C.
The following protocol was applied for the spheroid
assay: 48,000 HUVEC were mixed with 6 ml of metho-
coel/HUVEC medium and seeded as 100 μl drops in a
96-well U-bottom dish using a multipette. The cells
were incubated for 24 h in an incubator to form spheroids.
The day after, spheroids were collected, centrifuged and
the spheroid pellet was mixed with methocoel-mix The
collagen gel was prepared on ice and 500 μl of collagen gel
were added to the spheroid/methocoel solution, mixed by
pipetting and seeded on a 24-well culture dish for 30 min
in an incubator. The spheroids were cultured for 24 h at
37°C and 5% CO2. Spheroids were fixed with formalde-
hyde. For quantification, 10 spheroids were assessed for
cumulative sprout length, number of sprouts and number
of branch points.
In vivo angiogenesis assays
To gather information on the presence of functional circu-
lating PACs and how they are modulated by Saxagliptin in
type 2 diabetic subjects, we used the in vivo Matrigel plugangiogenesis assay with patients’ PBMC. Briefly, PBMC
were isolated with Histopaque (Sigma-Aldrich). Cell count
and viability were assayed with an automated BioRad
TC20 cell counter. Then, 3 × 106 PBMC were resus-
pended in 500 μL phenol-free Matrigel (BD, cat no.
356237) and implanted subcutaneously into the dorsum
of immunodeficient RAG-2/gamma(c) double knock-
out mice (in-house colony). Experiments involving ani-
mals were performed according to national guidelines
and according to the ‘Principles of laboratory animal care’
(NIH publication no. 85–23, revised 1985; http://grants1.
nih.gov/grants/olaw/references/phspol.htm). The experi-
ment was performed with PBMC of n = 5 type 2 diabetic
patients on Saxaglipthin therapy (>4 months) and n = 5
type 2 diabetic patients on non-incretinergic therapy. Mice
were anesthetized with 100 mg/ml Ketamine HCL and
20 mg/ml Xylazine. To minimize variability, the same
mouse received Matrigel plugs from a Saxagliptin-treated
and a control patient. Plugs were explanted 10 days later
for macroscopic inspection, histology (H&E staining), and
determination of the hemoglobin/protein content ratio
(Drabkin’s solution and Bredford reagent respectively,
Sigma-Aldrich), which is as a surrogate of perfusion.
In addition to the traditional Matrigel plug assay, we
also used the Directed In Vivo Angiogenesis Assay
(DIVAA, Amsbio, Abingdon, UK), which employs semi-
closed small silicone cylinders known as angioreactors,
filled with Matrigel with or without a growth factor
cocktail (fibroblast growth factor [FGF] + vascular endo-
thelial growth factor [VEGF]) specifically design to
stimulate vascular invasion. Angioreactors containing
patients’ PBMC were implanted subcutaneously in the
dorsal flanks of RAG-2/gamma(c) double knock-out
mice. Compared to the traditional plug assay, the sleek
design of angioreactors provides a standardized plat-
form for reproducible and quantifiable in vivo angiogen-
esis assays and prevents assay errors due to absorption
of Matrigel by the mouse. In the present protocol, each
anaesthesized mouse received implantation of 4 angior-
eactors, 2 containing cells from Saxagliptin-treated pa-
tients and 2 containing cells from control patients, each
with or without adding growth factors. Angioreactor
tubes were explanted 10 days later for gross inspection
of vascular invasion and determination of perfusion by
FITC Lectin detection, according to the manufacturer’s
protocol. As fluorescence labelled Griffonia simplicifolia
Lectin I binds to alpha-D-galactosyl and N-acetyl galac-
tosaminyl groups on the surface of endothelial cells,
Lectin content is a measure of angioreactor tube vascular
invasion.
Statistical analysis
Data are presented as mean ± standard error, or as per-
centage where appropriate. Normal distribution of the
Poncina et al. Cardiovascular Diabetology 2014, 13:92 Page 5 of 16
http://www.cardiab.com/content/13/1/92variables under investigation was verified using the
Kolmogorov-Smirnov test. Non normal variables were log
transformed. Comparison between means was performed
with the unpaired 2-tail Student’t t test. Comparison be-
tween more than 2 groups was performed with ANOVA.
The Bonferroni correction was used to account for mul-
tiple testing, where appropriate. Frequencies were com-
pared using the Chi square test. Statistical significance was
accepted at p < 0.05.
Results
Characterization of cultured pro-angiogenic cells
Pro-angiogenic cells (PACs) cultured from human PBMCs
constitute a heterogenous population composed mostly of
CD45+ lymphocytes and monocyte/macrophage lineage
cells, plus a small population of stem/progenitor cells,
possibly including EPCs [10]. Accordingly, we found
that PACs culture was comprised of i) small cells in the
lymphocytic morphologic (FSC vs SSC) gate, some of
which expressed KDR (21 ± 3%) and CD31 (36 ± 5%)
and can correspond to angiogenic T cells present in PACs/
early EPCs culture [18]; ii) larger mononuclear cells









































































Figure 1 Phenotypic characterization of cultured PACs. A) PACs were
side scatted (SSC) versus forward scatter (FSC) morphologic plot, lymphocy
identified and gated separately. Histograms reporting the expression of rele
KDR, CD34) are shown, together with mean percent expression from 3 rep
indicates the stained condition. B) Cells in the PACs culture were stained w
that were positive for both markers were compared in cultures obtained frthe monocyte-macrophage population. The monocytic/
lymphocytic cell ratio was 2.2 ± 0.1 and fairly constant
throughout experiments. As expected, expression of the
stem/progenitor cell marker CD34 was low (Figure 1A).
These data indicate that cells used in subsequent
experiments correspond to the PAC phenotype already
described in the literature. Cultured PACs were also
characterized by the double positivity for the (non-
unequivocal) endothelial markers acetylated LDL uptake
and Ulex-Lectin binding (Figure 1B). Interestingly, the
fraction of acLDL+Lectin+ cells in the PACs culture was
significantly lower in T2D compared to healthy controls
(30.8 ± 0.8% vs 36.0 ± 0.1%; p = 0.003). There were no dif-
ferences in the proportion of lymphocytic and monocytic
cells in PACs cultures of T2D versus healthy subjects (not
shown).
In vitro DPP-4 activity sources and effective enzymatic
inhibition
We preliminarily tested the non-pharmacologic DPP-4
inhibitor Diprotin-A and several concentrations of the
clinically available inhibitor Saxagliptin on DPP-4 activ-









characterized for surface marker expression by flow cytometry. In the
tic cells (LYMPHs) and monocyte-macrophages (MONOs) were
vant leukocyte (CD45, CD14, CD68) and endothelial markers (CD31,
licates. The red line indicates negative control, while the blue line
ith the endothelial markers acLDL and Ulex Lectin. The fraction of cells
om T2D or healthy control cells. *p < 0.05 T2D vs Ctrl.
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cient to reach maximal in vitro DPP-4 inhibition (~70%),
which was equal to the degree of inhibition achieved
using standard Diprotin-A concentrations (Figure 2A).
The 0.5 μM Saxagliptin concentration, which has the
same order of magnitude as the Cmax obtained in vivo in
humans after a 5 mg oral dose (0.1-0.3 μM), was chosen
for subsequent experiments.
DPP-4 exists as a soluble secreted protein or a














































































Figure 2 In vitro DPP-4 inhibition. A) Degrees of soluble DPP-4
inhibition in the conditioned medium by treatment of HUVECs with
Diprotin-A (DPA) or different Saxagliptin concentrations, relative to
the untreated control condition (CTRL). The experiment was
performed in triplicate. *p < 0.05 for ANOVA test. B) Expression of
membrane DPP-4 (CD26) on monocytic (MONOs) and lymphocytic
(LYMPHs) cells, identified by the side scatted (SSC) versus forward
scatter (FSC) morphologic plot of PACs culture. C) Soluble and
cellular DPP-4 activity and the extent of its inhibition of Saxagliptin
were tested in PACs cultured from CD14pos and CD14neg preselected
cells. *p < 0.05 for CD14− versus CD14+; †p < 0.05 for cellular versus
soluble (n = 3 replicates).signal transduction and adenosine metabolism [19]. In
cultured PACs, membrane DPP-4 (CD26) expression
was restricted to a subpopulation of lymphocytes (~50%
of the lymphocyte gate), whereas larger monocytic cells
were CD26-negative (Figure 2B). By using PACs cultured
from CD14pos or CD14neg cells, we compared soluble
(cell-free conditioned medium) and cellular (cell extracts)
DPP-4 activity and the effect of Saxagliptin. Soluble DPP-4
activity was 3–5 fold higher compared to cellular DPP-4
activity regardless of whether CD14pos or CD14neg cells
were present in the culture, and was inhibited >50% by
Saxagliptin. As expected, cellular DPP-4 activity was
higher in CD14neg(CD26+) cells compared to CD14pos
(CD26−) cells and it was inhibited >50% by Saxagliptin.
The DPP-4 activity of CD14pos cells, which do not express
significant amounts of membrane CD26, can be explained
by residual DPP activity provided by isoforms other than
DPP-4 (e.g. DPP-8 and −9) [20], that are partly inhibited
by Saxagliptin (Figure 2C). These data indicate that, in
PAC cultures, soluble activity is higher than cellular activ-
ity of DPP-4, the latter being mostly attributed to lympho-
cytes than to monocytic cells, while both soluble and
cellular DPP-4 are equally inhibited by Saxagliptin.Functional effects of Saxagliptin on PACs from healthy
controls and type 2 diabetic patients
We obtained PBMCs from n = 20 healthy blood donors
(50% males, aged 52 ± 3) free of diabetes and cardiovas-
cular disease, and n = 20 patients with T2D (Table 2).
We tested in vitro the ability of Saxagliptin 0.5 μM to
modify PACs properties, such as clonogenesis and prolif-
eration, adhesion, migration and tubulization. Given that
DPP-4 inhibition is supposed to affect PACs by protecting
SDF-1α (and other substrates) from enzymatic inactivation
[15], we evaluated the effects of Saxagliptin with and with-
out SDF-1α supplementation.Gene expression
First, we determined the expression of genes related to
PACs function and survival. In PACs isolated from T2D
patients compared to healthy control PACs, we found
significantly altered expression of BCL2, CDKN1A,
VCAM1, ICAM1, ITGB2 and DPP4 (Figure 3A). Im-
portantly, as previously noted [21], DPP4 expression
was markedly increased in diabetic PACs, providing a
rationale for pharmacologic DPP-4 inhibition. Expres-
sion of the selected genes in the entire PACs culture
was unaffected by treatment with Saxagliptin and/or
SDF-1α (not shown). In separated CD14+ monocytic PACs
compared to CD14− lymphocytic PACs, we found lower
expression of BCL2 and higher expression of CKDN1A
and VCAM1 at baseline (Figure 3B). In addition, Saxaglip-
tin treatment increased BCL2, CDKN1A, ITGB2 and
Table 2 Characteristics of type 2 diabetic patients included in the study
Variable In vitro study In vivo study
Saxagliptin Controls
Number 20 5 5
Age, years 65.2 ± 2.3 67.4 ± 2.6 66.1 ± 1.1
Sex male, % 65.0 80.0 60.0
Risk factors
BMI, kg/m2 30.3 ± 2.1 29.1 ± 1.9 28.7 ± 2.1
Waist circumference, cm 104.8 ± 3.9 102.8 ± 4.0 103.7 ± 5.1
Diabetes duration, years 11.3 ± 4.2 9.8 ± 3.6 12.4 ± 5.3
Fasting glucose, mg/dl (mmol/l) 166.2 ± 8.1 141.2 ± 6.7 138.8 ± 4.5
(9.2 ± 0.5) (7.8 ± 0.4) (7.7 ± 0.2)
HbA1c, % (mmol/mol) 8.4 ± 1.1 7.6 ± 1.6 7.8 ± 1.2
(68.3 ± 9.0) (59.6 ± 12.5) (61.7 ± 9.5)
Hypertension, % 75.0 80.0 100.0
Systolic blood pressure, mm Hg 138.1 ± 3.2 137.4 ± 4.2 140.1 ± 3.5
Diastolic blood pressure, mm Hg 86.7 ± 2.7 82.4 ± 3.8 84.5 ± 4.6
Total cholesterol, mg/dl (mmol/l) 188.2 ± 5.1 172.5 ± 4.9 185.4 ± 6.7
(4.9 ± 0.1) (4.4 ± 0.1) (4.8 ± 0.1)
HDL cholesterol, mg/dl (mmol/l) 46.6 ± 2.2 48.2 ± 1.1 46.9 ± 0.8
(1.2 ± 0.1) (1.2 ± 0.02) (1.3 ± 0.02)
LDL cholesterol, mg/dl (mmol/l) 98.1 ± 4.9 81.2 ± 3.2 88.4 ± 2.9
(2.5 ± 0.1) (2.1 ± 0.1) (2.7 ± 0.07)
Triglycerides, mg/dl (mmol/l) 149.3 ± 12.4 162.1 ± 14.8 138.2 ± 16.3
(1.7 ± 0.1) (1.8 ± 0.2) (1.6 ± 0.2)
Smoke, % 15.0 0.0 20.0
Complications
Coronary artery disease, % 25.0 20.0 0.0
Peripheral vascular disease, % 20.0 40.0 20.0
Cerebrovascular disease, % 40.0 40.0 20.0
Retinopathy, % 20.0 0.0 20.0
Nephropathy, % 25.0 0.0 0.0
eGFR < 60 ml/min/1.73 mq 0.0 0.0 0.0
Therapy
Insulin therapy, % 50.0 0.0 20.0
Oral therapy, % 45.0 100.0 80.0
Diet alone, % 10.0 0.0 20.0
ACE inhibitors/ARBs, % 80.0 80.0 80.0
Statin, % 65.0 60.0 80.0
Data are presented as mean ± standard error, or as percentage, where appropriate. There were no significant differences between the two groups of the in vivo
study.
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modest or absent in CD14− PACs.
Proliferation and clonogenesis
While the culture of PACs from healthy controls yielded
several rounded cell colonies in addition to interspersedcells, colonies were rarely seen during culture of PACs
from T2D (Figure 4A). As expected from a PACs cul-
ture, the proliferation rate was low (3-5%). Treatment
with Saxagliptin alone, but not in combination with
SDF-1α, doubled the percentage of cells in the S + G2/M




























































































































































































Figure 3 Gene expression analysis of diabetic and healthy PACs. A) Gene expression was determined in the whole PACs population
obtained from type 2 diabetic patients (T2D) and healthy subjects (Ctrl). Expression is reported relative to the housekeeping gene as 2ΔCT. Note
the logarithmic scale. *p < 0.05 T2D versus Ctrl. B) Expression of a selected number of genes found to be differentially expressed in (A) was tested
in CD14+ monocytic and in CD14− lymphocytic PACs separately. *p < 0.05 in CD14+ vs CD14− cells; †p < 0.05 versus the control condition.
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http://www.cardiab.com/content/13/1/92subjects’ PACs (Figure 4B). It has been previously reported
that DPP-4 cleaves and inactivates several hematopoietic
growth factors, suggesting that DPP-4 inhibition may
sustain hematopoiesis [22]. Saxagliptin and/or SDF-1α did
not restore colony formation during PAC culture from
T2D PBMCs, but tended to increase the number of
colonies of PACs cultured from healthy controls. Further-
more, using the methylcellulose mouse bone marrowhematopoietic colony assay (Figure 4C), we report that
treatment with Saxagliptin + SDF-1α was indeed able to
increase the total number of hematopoietic colonies. A
breakdown analysis showed that treatment with Saxaglip-
tin + SDF-1α induced consistent trend increases of most
colony types, especially granulocytes and macrophages
(Figure 4D). These data indicate that, unlike in diabetic








































































Figure 4 Effects of Saxagliptin on clonogenesis and proliferation. A) Representative microphotographs of PACs culture from type 2 diabetic
patients and healthy controls exposed to Saxagliptin with or without SDF-1α supplementation. B) Analysis of cell cycle phases in cultured PACs of
healthy subjects (left) and type 2 diabetic patients (right). *p < 0.05 versus the unstimulated control condition (Ctrl). C) Representative microphotographs
of murine hematopoietic colonies exposed to Saxagliptin with or without SDF-1α supplementation. D) Quantification of total (left) and types
(right) of hematopoietic colonies in relation to treatment with Saxagliptin, with or without SDF-1α supplementation. *p < 0.05 versus the
unstimulated control condition (Ctrl).
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http://www.cardiab.com/content/13/1/92proliferation, while the co-treatment with SDF-1α pro-
motes hematopoietic clonogenesis. Differences in the pro-
liferative response between healthy control and diabetic
PACs may be related to the differential baseline expression
of genes regulating cell cycle and survival, such as
CDKN1A (encoding p21) and BCL2 (Figure 3). Saxagliptin
and/or SDF-1α did not significantly affect the percentage
of acLDL+Lectin+ cells (not shown).
Adhesion
Adhesion of PACs to mature endothelial cells represents
an important step for the pro-angiogenic and vascular
repairing activity of PACs. We thus tested adhesion of
PACs to HUVECs in vitro and found that the number of
adherent PACs was unaffected by treatment in healthy
controls, while Saxagliptin significantly increased adhesion
of T2D PACs in the presence of SDF-1α (Figure 5A, B).
The significantly lower baseline adhesive capacity of diabetic
PACs compare to control PACs and the differential
response to Saxagliptin + SDF-1α may be related to the
different baseline expression of adhesion molecule genes,
such as ICAM1, VCAM1 and ITGB2 (Figure 3).
We used this assay to understand the relative contri-
bution of membrane bound DPP-4 (CD26), which is
expressed on CD14neg, but not on CD14pos PACs.
Therefore, we cultured PACs from healthy controlsstarting from immunomagnetically purified populations
of CD14pos and CD14neg cells. We found that Saxaglip-
tin reduced adhesion by CD14posCD26neg cells and in-
creased adhesion by CD14negCD26pos cells (Figure 5C).
This indicates that inhibition of soluble DPP-4 only (as
in cultures of CD14pos cells) and inhibition of both iso-
forms (as in cultures of CD14neg cells) can have oppos-
ing effects on PACs function and explains, at least in
part, why Saxagliptin has modest or no overall net effect
on the heterogeneous PACs culture. In addition, to bet-
ter understand which is the saxagliptin-responsive cell
type in the heterogeneous PACs culture, we separated
CD14+ from CD14− PACs cultured from unselected
PBMCs in the presence of Saxagliptin and/or SDF-1α. We
found that the adhesive capacity of CD14+ monocytic
PACs was significantly higher than that of CD14− lympho-
cytic cells, and that it was stimulated by Saxagliptin with
or without SDF-1α (Figure 5D).Migration
PACs migration was assessed using a transwell assay, with
the chemokine SDF-1α being the prototypical positive
control [13]. We found that the percentage of migration
was increased by SDF-1α using both healthy and diabetic
































































































































































Figure 5 Effects of Saxagliptin on adhesion of PACs. A) Representative microphotographs of red-labelled PACs adhering onto HUVEC
monolayers (nuclei labelled in bue with Hoechst), using cells from type 2 diabetic patients and healthy controls exposed to Saxagliptin with or
without SDF-1α supplementation. B) Quantification of adherent PACs from type 2 diabetic (T2D) and healthy (Ctrl) subjects in the untreated condition
and according to the treatment with Saxagliptin, with or without SDF-1α supplementation. *p < 0.05 versus the untreated control condition (Ctrl).
C) Effects of Saxagliptin on cell adhesion was determined in cultures of healthy PACs obtained from pre-selected CD14+ and CD14− cells. *p < 0.05
versus the untreated control condition (Ctrl). D) Baseline adhesion and effects of Saxagliptin +/− SDF-1α was tested in separated CD14+ and
CD14− PACs, after cells were cultured from unselected PBMCs. *p < 0.05 in CD14+ vs CD14− cells; †p < 0.05 versus the control condition.
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http://www.cardiab.com/content/13/1/92SDF-1α did not affect migration of both control and
diabetic PACs (Figure 6). It should be noted that the
absolute numbers of migrating cells in this system was
low, thus limiting the chance of reporting small effects
as significant.Tube formation
Tubulization by HUVECs co-cultured with PACs was
assessed using the 2D Matrigel assay (Figure 7A). It is
well known that PACs do not spontaneously form tubules
















































































Figure 6 Migration of PACs cultured from type 2 diabetic patients (A) and healthy controls (B) in the presence and in the absence of
Saxagliptin and SDF-1α was assessed using a transwell system. *p < 0.05 versus the untreated control condition (Ctrl).
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http://www.cardiab.com/content/13/1/92endothelial cells [10]. We found that only T2D PACs
treated with Saxagliptin + SDF-1α were able to increase
tube length formation by HUVECs, while there was no
effect on healthy PACs (Figure 7B-C). The number of
branching points was not significantly different in T2D
compared to controls and was unaffected by treatments
(not shown). In addition, we evaluated the tube supportive
capacity of CD14+ PACs versus CD14− PACs and how
they are affected by treatments. We found that HUVECs
co-cultured with CD14+ monocytic PACs showed in-
creased tube formation compared to co-culture with
CD14− lymphocytic PACs. Moreover, tube formation by
HUVECs/CD14+ PACs was significantly increased by
Saxagliptin treatment compared to the control condition
(Figure 7D). Most of labelled PACs co-cultured with
HUVECs remained located in cellular islands at tube
intersections, while only some contributed physically to
tube formation. No difference was seen in the percent-
ages of tubes bearing integrated CD14+ (15 ± 4%) versus
CD14− PACs (12 ± 2%; p = 0.41) (Figure 7E).
Finally, as the tube assay is strictly dependent on the
cooperation between HUVECs and PACs, we explored
the effect of Saxagliptin on in vitro angiogenesis assays
of isolated HUVECs. We found that, using both the
2D Matrigel tubulisation assay and the spheroid
sprouting assay, Saxagliptin modestly but significantly
reduced in vitro angiogenesis by mature endothelial
cells (Figure 8A, B).
In vivo effect of Saxagliptin on angiogenesis induced by
circulating cells
To assess the relevance of the pro-angiogenic effects of
Saxagliptin on circulating PACs compared to the possibleanti-angiogenic effects on mature ECs, we used in vivo
Matrigel assays. First, PBMCs from T2D treated with Sax-
agliptin (n = 5) and PBMCs from T2D patients on non-
incretinergic therapy (n = 5; see Table 2) were embedded
into Matrigel plugs and implanted subcutaneously into
immunodeficient mice. Angiogenesis in this model is me-
diated by the cooperation between the intraplug cells (the
circulating source of PACs) and mouse ECs invading the
plug. We found a non-significant increase in vascular plug
invasion and hemoglobin content (a surrogate of plug
vascularization) in plugs containing PBMC from
Saxagliptin-treated compared to those from untreated
diabetic patients (Figure 8C). To further address this
issue, we used the Directed In Vivo Angiogenesis Assay
(DIVAA), which allows a more reproducible quantifica-
tion of in vivo angiogenesis. DIVAA angioreactor tubes
were implanted with cells obtained from saxagliptin-
treated and non incretin drug-treated T2D patients,
with or without growth factors (GF) that stimulate
angiogenesis. We did not find significant differences
in the Lectin content (a proxy of perfusion in DIVAA
experiments) in tubes containing cells from saxagliptin-
treated patients versus controls in either the presence
or absence of GF. However, the difference between Lec-
tin content in tubes with and without GF, indicative of
the ability of GF to increase PBMC-mediated angiogen-
esis in each patient, was significantly higher (p = 0.03)
for saxagliptin-treated patients compared to controls
(Figure 8D).
Discussion
In the present study, we show that DPP-4 inhibition with









































































































































Figure 7 Effects of Saxagliptin on migration and tubulisation of PACs. A) Representative microphotographs of tube formation in 2D
Matrigel by HUVECs co-cultured with PACs from type 2 diabetic patients and healthy controls exposed to Saxagliptin with or without SDF-1α
supplementation. B-C) Quantification of total tube length formation by HUVECs alone and HUVECs co-incubated with PACs either untreated (Ctrl)
or treated with Saxagliptin and/or SDF-1α. Panel B shows data obtained with PACs from type 2 diabetic patients, while panel C shows data
obtained with healthy PACs. *p < 0.05 versus HUVECs alone, set at 1.0. D) Quantification of total tube length formation by HUVECs alone and
HUVECs co-incubated with CD14+ or CD14− PACs from healthy controls. *p < 0.05 in CD14+ vs CD14− cells; †p < 0.05 versus the control condition.
E) Red-labelled PACs co-cultured with HUVECs in the tube forming assay were imaged under an inverted fluorescence micriscioe to detect their
spatial localization and quantify tubes with integrated CD14+ and CD14− PACs.
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http://www.cardiab.com/content/13/1/92T2D in vitro and improves inducible angiogenesis by pa-
tients’ cells in vivo. We have previously shown that DPP-4i
increases circulating EPCs in a similar population of T2D
subjects [15]. Herein, we add to those findings showing
that, not only the level, but also the function of vascular
protective cells can be improved by DPP-4i treatment.PACs derived from PBMC cultures differ from EPCs
quantified ex vivo by flow cytometry, as they are com-
posed of a heterogenous population of angiogenic T cells
and monocyte-macrophages, plus a small population of
progenitor cells [10]. The pro-angiogenic and vascular
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Figure 8 Effects of Saxagliptin on angiogenesis. A) The effect of Saxagliptin on tube formation by HUVECs in 2D Matrigel was assessed. Total
tube length as well as average tube length are reported. *p < 0.05 (n = 3 replicates) for Saxagliptin-treated versus the untreated control condition
(Ctrl). B) The effect of Saxagliptin on sprouts formation by spheroids of HUVECs was assessed. Total sprouts length as well as the number of
sprouts are reported. *p < 0.05 (n = 3 replicates) for Saxagliptin-treated versus the untreated control condition (Ctrl). C) In vivo angiogenesis in
Matrigel plugs by PBMCs isolated from Saxagliptin-treated and non-incretinergic drug treated type 2 diabetic patients (n = 5/group). Representative
figures, as well as quantification of Hb content are shown. D) PBMC from Saxagliptin-treated and non-incretinergic drug treated type 2 diabetic patients
(n = 5/group) were also used for the Directed In Vivo Angiogenesis Assay (DIVAA) using angioreactor tubes with (+) and without (−) growth factors
(GF). After visual inspection, Lectin content was determined as an indicator of vascular invasion of the tube. Lectin content quantification in tubes
without and with GF, as well as the difference between the two are shown. *p < 0.05 Saxa versus Ctrl.
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http://www.cardiab.com/content/13/1/92demonstrated in pre-clinical studies [23,24]. In addition,
autologous administration of bone marrow derived PACs
was shown to improve left ventricular ejection fraction
in patients with acute myocardial infarction [25], con-
firming the protective cardiovascular effects of these
cells in humans. The mechanisms whereby PACs achieve
vascular protection in vivo are not entirely clear, but data
suggest that they are mainly derived from an intense
paracrine activity, rather than definite endothelial differ-
entiation and integration [2]. Indeed, although a signifi-
cant ontologic overlap between the endothelium and
hematopoietic cells exists in the embryo [26], epigenetic
brakes prevent blood-derived PACs to differentiate intomature endothelium in adulthood [27]. The heteroge-
neous composition of PACs culture could be seen as a
limit to the interpretation of the present findings. How-
ever, it should be noted that late EPCs and ECFC can be
only stochastically isolated from peripheral blood of dis-
eased subjects [10], thus limiting reproducibility of the
findings. Whether PACs mainly represent an in vitro
artefact or they also exist in vivo is a matter of debate,
although the discovery of the so-called haemogenic endo-
thelium suggest that endothelial-hematopoietic overlaps
can occur also in adulthood [26].
Several authors have reported that diabetes induces
PACs dysfunction, through epigenetic changes [28], eNOS
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http://www.cardiab.com/content/13/1/92modulation [29], and humoral factors [30]. We herein
confirm that PACs isolated from T2D have impaired
differentiation, clonogenesis and adhesion compared to
PACs isolated from healthy controls. This was associ-
ated with changes in the expression of genes related to
adhesion and regulation of cell cycle. Such differences,
however, cannot be directly attributed to diabetes per se,
because T2D patients were also older than controls and
had additional cardiovascular risk factors. The rationale
for including healthy controls instead of matched non-
diabetic patients was to assess the effects of Saxagliptin
within each group and understand whether DPP-4i influ-
ences both diseased and healthy PACs. Interestingly, we
found that, with the exception of proliferation, only PACs
from T2D patients improved their function after treat-
ment with Saxagliptin. This can be attributed to the
marked upregulation of DPP-4 gene expression in diabetic
PACs. We have previously shown that DPP-4 activity is
increased in serum/plasma of T2D compared to non-
diabetic patients and is not directly related to glucose
control [21]. DPP-4 exists as either a soluble or mem-
brane bound (cellular, CD26) isoform and the relative
contribution of the 2 to the total DPP-4 activity and its
biological effects were previously unknown. We show
that soluble DPP-4 activity is higher than cellular DPP-4
activity, which is restricted to a lymphocyte subpopulation.
This is particularly important in cultures of PACs, which
are composed of angiogenic T cells and endothelial-like
monocyte-macrophages. Indeed, we found that, though
Saxagliptin did not significantly affect adhesion of healthy
PACs, when PACs were isolated starting from CD14+
(CD26/DPP-4−) cells or CD14−(CD26/DPP-4+) cells, the
effects of Saxagliptin on adhesion were opposite. In
addition, among the heterogeneous PACs population,
CD14+ monocytic PACs compared to CD14− lympho-
cytic PACs showed higher functionality at baseline and
were much more responsive to Saxagliptin-induced
gene expression changes and stimulation of adhesion
and tube supporting capacity. While such differences
can be the result of cell-type specific responses to Saxa-
gliptin, it is possible that cellular DPP-4 inhibition exerts
different effects compared to soluble DPP-4 inhibition.
While membrane bound DPP-4 may transduce intracellu-
lar signals and is a cofactor of adenosine deaminase [19],
secreted DPP-4 is supposed to act mainly through cleav-
age of soluble mediators. Indeed, we found that Saxaglip-
tin improved whole PACs function only in the presence of
SDF-1α supplementation, whereas Saxagliptin alone or
SDF-1α alone less effective. Based on the low SDF-1α con-
centrations in the medium (fg/ml) compared to the high
DPP-4 expression/activity, it is rationale that only simul-
taneous SDF-1α supplementation and DPP-4 inhibition
provided significant biological effects, a finding that sup-
ports the mechanistic theory whereby DPP-4i affects PACsby protecting SDF-1α (and possibly other factors) from
enzymatic degradation. In addition to improving PACs
function, DPP-4 inhibition also mobilizes EPCs via SDF-
1α [15]. This synergistic effect is expected to promote
favourable outcomes in several diabetic complications
[31], including wound healing [32,33].
In contrast to the positive effects exerted by Saxaglip-
tin + SDF-1α on T2D PACs, Saxagliptin +/− SDF-1α did
not affect function of healthy control PACs when evalu-
ated in the entire population, but differentially affected
function of CD14+ monocytic versus CD14− lymphocytic
cells. Saxagliptin also reduced angiogenesis by mature
endothelial cells in vitro, suggesting cell-type specific
effects. Therefore, to understand the overall net effects
of Saxagliptin on angiogenesis in vivo, we used PBMCs
isolated from Saxagliptin-treated and from control T2D
patients treated with non-incretinergic drug. The Matri-
gel plug assay showed non-significantly higher perfusion
obtained with Saxagliptin-treated compared to control
cells. As this assay has wide variability depending on
how the plug develops and is adsorbed in the mouse, we
also used the more reliable and quantitative Directed In
Vivo Angiogenesis Assay (DIVAA). We found that the
extent to which growth factors (VEGF + FGF) increased
vascular invasion of the angioreactor was significantly
higher for Saxagliptin-treated compared to control cells.
This suggests that Saxagliptin increases the ability of cir-
culating cells to respond to pro-angiogenic growth factors,
possibly protecting them from enzymatic degradation.
Conclusions
Reversal of T2D PACs dysfunction and stimulation of
inducible angiogenesis may translate in a microvascular
[34] and cardiovascular protective activity of DPP-4i.
While pooled data from short-term phase III randomized
clinical trials in selected T2D patients showed potential
cardiovascular benefit of Saxagliptin [35], the Saxagliptin
Assessment of Vascular Outcomes Recorded in Patients
with Diabetes Mellitus (SAVOR) clinical trial, conducted
on >16,000 T2D patients with a history or risk factors for
cardiovascular events, showed a neutral effect of Saxa-
gliptin on the rate of ischemic events [36]. However, this
event-driven study was terminated after just a median
follow-up of 2.1 years, thus limiting the chance that
protective effects of Saxagliptin translated into an event
rate reduction. So far, experimental pre-clinical and
clinical findings widely argue for potential cardiovascular
protection by DPP-4i. The observation that Saxagliptin re-
stores the function of PACs from T2D patients represents
an additional step toward a better understanding of the
pathobiology of DPP-4 in diabetes. PACs function can
be restored by glucose normalization, as shown in
islet-transplated type 1 diabetic patients [37]. There-
fore, Saxagliptin may also impact PACs pro-angiogenic
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http://www.cardiab.com/content/13/1/92activity by improving glucose control [38]. As HbA1c
was only slightly and not significantly lower in Saxagliptin-
treated patients compared to patients on non-incretinergic
therapies, pleiotropic extraglycemic effects are likely
implicated.
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